AB 16B5

Drug Profile

AB 16B5

Alternative Names: 16B5; AB-16B5; AB-sCLU mAB; Anti-clusterin monoclonal antibody - Alethia Biotherapeutics

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Research Council Biotechnology Research Institute
  • Developer Alethia BioTherapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Clusterin inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Apr 2017 Adverse events, efficacy and pharmacokinetics data from the phase I trial in solid tumours presented at the 108th annual meeting of the American Association for Cancer Research (AACR-2017)
  • 21 May 2015 Alethia Biotherapeutics is planning a phase I trial in Solid tumours (Late-stage disease) in Canada (NCT02412462)
  • 01 Apr 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV) (NCT02412462)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top